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Biological Mechanism Profiling Using an Annotated
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enchymal transition, and altered adhesiveness and
growth rates [7]. In this study, we developed a method
for integrating existing biological information related to
David E. Root, Stephen P. Flaherty, Brian P. Kelley,
and Brent R. Stockwell*
Whitehead Institute for Biomedical Research
9 Cambridge Center a large number of compounds to study the biological
mechanisms sufficient for killing or arresting the growthCambridge, Massachusetts 02142
of a human cancer cell line derived from a clinical
specimen.
The National Cancer Institute has assembled a largeSummary
collection of compounds with either potential or demon-
strated activity in cancer and viral-related assays. OurWe present a method for testing many biological
approach is distinct from the NCI’s approach in that wemechanisms in cellular assays using an annotated li-
obtained and tested compounds with a more diversebrary of 2036 small organic molecules. This annotated
range of biological activities, including neurologicallycompound library represents a large-scale collection
active compounds, antidiabetic compounds, controlledof compounds with diverse, experimentally confirmed
substances, and compounds with many other activitiesbiological mechanisms and effects. We found that this
unrelated to cancer and infectious diseases. Our hy-chemical library is (1) more structurally diverse than
pothesis was that an annotated compound library cov-conventional, commercially available libraries, (2) en-
ering such a wide range of activities would be usefulriched in active compounds in a tumor cell viability
in many different cell-based assays. This collection isassay, and (3) capable of generating hypotheses re-
complementary to the NCI collection, and we have re-garding biological mechanisms underlying cellular
cently begun to compile a composite set comprisingprocesses. We elucidated biological mechanisms rel-
both our collection and the NCI diversity set of 1990evant to the antiproliferative activity of 85 compounds
compounds (vide infra).from this library that were selected using a high-
Many previous studies [8–14] have identified specificthroughput cell viability screen. We developed a novel
compounds that prevent the growth of tumor cells, aautomated scoring system for identifying statistically
number of which have been developed into clinicallyenriched mechanisms among such a subset of com-
effective anticancer drugs. In such cases, much effortpounds. This scoring system can identify both pre-
was required to identify the specific proteins targetedviously known and potentially novel antiproliferative
by each of these antitumor agents. We hypothesizedmechanisms.
that an ACL composed of well-studied organic com-
pounds with diverse biological mechanisms not limited
Introduction to those known to affect tumor cell viability would allow
for rapid elucidation of new biological targets and mech-
Small organic molecules have been used to mimic ge- anisms relevant to tumor cell viability, and eventually
netic mutations for the study of biological systems in an other cellular processes of interest. In our view, such a
approach called chemical genetics [1–4]. This strategy result could be achieved by testing annotated com-
generally requires screening tens of thousands of or- pounds for their effects on tumor cell proliferation, iden-
ganic compounds in cellular assays to identify a small tifying the subset of these compounds that prevent tu-
number of active compounds and then requires signifi- mor cell proliferation, and determining the biological
cant additional effort to illuminate the mechanistic basis mechanisms that are statistically enriched among this
for each compound’s activity [3]. Just as genetic ap- group of compounds relative to the collection as a
proaches have benefited from the use of large collec- whole. We report herein the successful execution of this
tions of annotated genes and genetic probes [5, 6], biological mechanism profiling strategy.
chemical genetic approaches might benefit from the use
of annotated compounds. We set out to identify, collect,
and assemble into a screenable format thousands of Results and Discussion
small molecules with experimentally verified biological
mechanisms and activities. We assembled a collection of 2036 biologically active
Our goal was to use such an annotated compound compounds and assigned each compound one of 169
library (ACL) to capture information that previously broad biological mechanism descriptors (“primary de-
would have required many target-identification experi- scriptors”). Ninety-nine of these primary descriptors are
ments. We chose to focus, in our initial study, on aspects represented by three or more compounds (Table 1), illus-
of viability and proliferation unique to tumor cells. Prolif- trating the wide variety of biological mechanisms probed
eration rate is one of many cellular alterations associ- by the compounds present in the library.
ated with cancer that can be used as the basis for a All of the compounds in our ACL have biological activ-
chemical genetic screen; others include activation of ity, but only a small percentage of compounds in con-
angiogenesis and metastatic potential, epithelial to mes- ventional compound libraries are expected or reported
to have biological activity. We sought to identify differ-
ences in distributions of molecular descriptors between*Correspondence: stockwell@wi.mit.edu
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Table 1. Representative Classes of Biologically Active Compounds and the Number of Compounds in Each Class
ACE inhibitor 6 Cl ion signaling modulator 3 muscle relaxant 6
actin ligand 5 cyclooxygenase inhibitor 29 Na ion signaling 18
adenosine receptor ligand 78 dehydrogenase modulator 5 neuronal function 9
adenylate cyclase ligand 15 detergent 3 nitric oxide signaling 45
adrenergic receptor ligand 105 diacylglycerol kinase 3 opioid receptor ligand 32
modulator
aa metabolism 12 diuretic 4 P450 modulator 10
aminopeptidase inhibitor 7 DNA binding agent 66 PARP 5
amphetamine 7 DNA gyrase ligand 5 phosphatase ligand 4
analgesic 11 dopaminergic 111 phosphodiesterase 14
anesthetic 12 dye (cell staining) 9 phospholipase 13
antibacterial agent 46 enkephalinase ligand 4 PI3K inhibitor 3
antibiotic (general) 32 folate metabolism modulator 9 platelet aggregation inhibitor 6
anticonvulsant 3 G protein modulator 3 prostaglandin 16
antifungal 11 GABA receptor ligand 45 protease inhibitor 28
antihypertensive agent 5 glucose modulator 5 protein kinase inhibitor 62
antiinflammatory agent 6 glutamatergic agent 88 protein synthesis inhibitor 8
antimalarial agent 4 glutathione modulator 4 ribosome activity modulator 8
antioxidant 15 glycoprotein synthesis 3 RNA biosynthesis inhibitor 5
antiviral agent 9 glycosidase inhibitor 9 serotonergic agent 71
aromatase inhibitor 4 gonadotropin 6 steroid 67
ATPase inhibitor 10 guanylate cyclase 4 taste receptor ligand 5
benzodiazepine 5 histamine modulator 37 thymidylate synthase 8
inhibitor
Ca ion signaling modulator 45 imidazoline modulator 4 TNF modulator 5
calmodulin inhibitor 24 ion signaling (general) 36 topoisomerase ligand 7
cannabinoid receptor ligand 6 K ion signaling modulator 17 tryptophan hydroxylase 7
ligand
caspase inhibitor 5 L-aa decarboxylase inhibitor 8 tubulin ligand 20
ceramide signaling modulator 7 lectin ligand 3 tyrosine hydrolase ligand 6
cGMP modulator 3 lipid biosynthesis modulator 9 tyrosine kinase ligand 25
ion chelator 7 lipoxygenase ligand 5 vanilloid receptor ligand 3
cholecystokinin modulator 6 melatonin modulator 3 vasodilator 8
cholesterol biosynthesis 5 metal ion modulator 3 venom 7
modulator
cholinergic agent 79 mitochondrial modulator 3 vitamin 18
cholinesterase inhibitor 16 monoamine oxidase inhibitor 15 xanthine oxidase inhibitor 4
Abbreviations: amino acid, aa; angiotensin converting enzyme, ACE; adenosine triphosphate, ATP; cyclic guanosine monophosphate, cGMP;
deoxyribonucleic acid, DNA; gamma amino butryic acid, GABA; cytochrome P450, P450; poly(ADP ribose) polymerase, PARP; phosphatidylino-
sitol-3-kinase, PI3K; and tumor necrosis factor, TNF.
these two types of libraries. We compared the distribu- This SOM illustrates that the Comgenex library is largely
composed of molecules in small and densely packedtions of 138 molecular descriptor values for the 1613
compounds in the ACL with associated electronic struc- regions of chemical space, likely due to the combinato-
rial nature of the library design.ture files versus 20,000 compounds in a synthetic com-
binatorial library (Comgenex) and 29,996 compounds in The small number of compounds in the ACL covers
a significantly larger range of descriptor values thana commercially available synthetic compound collection
(Chembridge). The two latter libraries are typical of those the 20,000 compounds and 29,996 compounds in the
Comgenex and Chembridge libraries, respectively, (Fig-used in high-throughput, chemical genetic screens [15–
18]. As seen in Figure 1A, the middle 80% of descriptor ure 1) despite the fact that a major criterion in the design
of the latter two libraries was structural diversity [18,values for the ACL has a wider range than either the
Chembridge or Comgenex libraries for most descriptors 20]. The ACL was designed to have broad functional
diversity, and it incorporates compounds affecting a(average ratio of ranges, ACL/Chembridge  1.8),
whereas the Chembridge and Comgenex libraries have wide range of biological mechanisms. The observation
that the ACL is structurally as well as functionally diversesimilar ranges for most descriptors (average ratio of
ranges, Comgenex/Chembridge 1.1). The middle 98% is intriguing but implies no causal relationship between
structural and functional diversity. However, these resultsof ACL descriptor values exhibits an even greater spread
relative to the corresponding range for the Chembridge do demonstrate that some commercial libraries fail to
test large biologically relevant descriptor ranges, and,and Comgenex libraries (Figure 1B). We used a self-
organizing map (SOM) [19] to cluster compounds from while there is no evidence that structural diversity per
se will yield a higher hit rate, a more structurally diversethe three libraries based on their descriptor values and
to illustrate that the ACL spans a different region of library can yield a more structurally diverse set of active
compounds.descriptor space and is more diverse than either com-
mercial library (see Supplemental Figure S1 at http:// We anticipated that compounds with previously de-
scribed biological activity would have a greater proba-www.chembiol.com/cgi/content/full/10/9/881/DC1).
Figure 1. An Annotated Library of Biologically Active Compounds Is More Diverse Than Conventional Compound Libraries
(A and B) The plots depict the upper and lower bounds for values of 138 molecular descriptors for the middle n% of descriptor values in
three libraries (ACL, Chembridge [CB], and Comgenex [CGX]), where n  80 (A) and 98 (B). In (A), the upper and lower red lines indicate the
90th and 10th percentile values of each molecular descriptor for the CB library. Similarly, the dark blue and light blue lines indicate the 90th and
10th percentile values for the ACL and CGX libraries, respectively. The descriptors were sorted in order of increasing range (upper bound
minus lower bound) in the ACL library, resulting in an increasing gap between dark blue lines.
(C) Scatter plot of two molecular descriptors for all three libraries. The values of polar van der Waals surface area and cyclicality, as defined
by Petitjean [49], were plotted for 1613 ACL compounds (blue), 29,996 CB compounds (red) and 20,000 CGX compounds (green).
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bility than random compounds of being active in new would serve as a starting point for 85 separate time-
intensive, target-identification projects. Instead, we in-cellular assays because their biological molecular
mechanisms might be operative in a new context. To tegrated and analyzed the existing literature on these
85 compounds to extract biological mechanisms en-test this hypothesis, we evaluated the ability of the ACL
and the Comgenex libraries to selectively inhibit the riched in this group of compounds relative to the entire
ACL. The results of such an analysis can be used toproliferation of an engineered human tumor cell line [21].
This cell line was produced by introduction of genetic guide and prioritize validation experiments.
To facilitate analysis of existing literature, we devel-elements encoding the simian virus 40 large T (LT) and
small T (ST) oncoproteins, the telomerase catalytic sub- oped automated algorithms for both mechanistic anno-
tation of compounds and identification of enrichedunit (hTERT), and an oncogenic allele of RAS into primary
human fibroblasts [22, 23]. When all four of these pro- mechanisms among a subset of compounds. One obsta-
cle to making full use of the existing literature is thatteins are expressed together, these cells (BJELR) ac-
quire characteristics of tumor cells, such as growth in most published reports associate a single biological
mechanism with any given small molecule, despite thesoft agar and tumor formation in mice [22, 23]. We tested
the effects on proliferation of BJELR and BJ cells of the fact that within cells many diverse molecular changes
are observed after treatment with each compound.ACL and Comgenex compounds at 4 g/ml for 48 hr.
By measuring the staining of these cells with calcein Compound annotation that accommodates multiple ef-
fects associated with each compound is critical for cor-acetoxymethyl ester (calcein AM) [24], a viability dye,
we found that 2.5% of the ACL compounds inhibited rectly inferring mechanisms of action. We developed
a comprehensive vector-based strategy for compoundproliferation of engineered BJELR tumor cells by at least
80%, whereas only 0.69% of the Comgenex compounds annotation that is compatible with multiple mechanisms
for each compound. We generated a vector for eachdid so, indicating a 4-fold enrichment for such antitumor
agents in the ACL. More importantly, when we tested compound with a quantitative score for each of 12,755
different biological mechanisms, comprising the 169 pri-these compounds for tumor cell selectivity versus pri-
mary cells (i.e., the ratio of concentrations required to mary descriptors, 200 Medline medical subject heading
terms related to pharmacology, and more than 12,000achieve 50% reduction of calcein staining in tumor cells
and primary cells), we found that 1% of the ACL com- human gene names (our “12K annotation”). For each
compound in the ACL, we scored the relevance of eachpounds were at least 4-fold selective for killing of tumor
cells versus primary cells, but only 0.01% of the Com- biological mechanism term by performing a search of
the more than 11 million records of the Medline biomedi-genex compounds met this selectivity threshold. Since
primary cells are normal, nontumorigenic cells freshly cal literature database for the number of co-occurrences
of the biological mechanism term and the given com-derived from human tissue, selectivity for tumor cells
compared to these cells indicates specificity for mecha- pound name in the title, abstract, or keyword fields (Fig-
ure 3).nisms particular to tumor cells. Thus, there was enrich-
ment of compounds with tumor cell-selective killing in To determine the reliability of this 12K annotation, we
compared it with our manual annotation. In a randomlythe ACL relative to a combinatorial library [21]. It should
be noted that although we selected compounds for in- chosen subset of 235 compounds, 210 (89%) had manu-
ally assigned primary descriptors that were the sameclusion in the ACL based on reported biological activity,
none of the compounds had previously been tested in as one of the top three ranked mechanism descriptors
assigned by the automated annotation method (Figurethis assay system, i.e., for their ability to kill engineered
tumor cells selectively relative to their isogenic primary 3A), indicating reasonable agreement between manual
and automated annotation methods. The automated an-cell counterparts.
In a second experiment with the ACL, we sought to notation can be updated regularly to incorporate the
most recent literature and to add literature annotationtest its ability to uncover mechanisms associated with
particular cellular processes, in this case tumor cell pro- for new ACL compounds. Future studies may focus on
incorporating additional biological mechanism termsliferation and viability. We treated A549 lung carcinoma
cells [25, 26] with each ACL compound in triplicate for and databases and on implementing natural language
processing systems [27] to improve further the accuracy1, 2, and 3 days to identify both rapidly and slowly acting
antiproliferative and cytotoxic mechanisms (Figure 2A). of automated annotation. Recently, a similar strategy
has been applied to the related problem of gene networkOf the 2036 compounds in our collection, 85 caused a
50% or more reduction in staining of A549 cells with the analysis [28].
We used our 12K annotation to identify, in an unbiasedviability dye calcein AM [24] (Table 2). A number of these
compounds (37) have not been previously tested in the fashion, 28 mechanisms that were statistically overre-
presented among the 85 active compounds identifiedNCI’s multiyear comprehensive compound screening
effort [10], and 25 of these compounds were not in the in our antitumor screening procedure versus the parent
library (Table 3; see Supplemental Data at Chemistry &NCI collection of 249,071 compounds (see Supplemen-
tal Table S1 at http://www.chembiol.com/cgi/content/ Biology’s website for details). Our website (http://staffa.
wi.mit.edu/stockwell/) allows entry of a set of compoundfull/10/9/881/DC1).
The abundance of active compounds and large names from the ACL and returns a list of enriched mech-
anisms in this subset of the ACL. We refer to this proce-amount of associated literature-based information
makes it difficult to follow up on each active compound dure for identifying enriched biological mechanisms as
Global Mechanism Extraction. The list of enriched bio-with a manual search of the literature. In a traditional
chemical genetic approach, the 85 active compounds logical mechanisms consists of general antiproliferative
Mechanism Profiling with Annotated Compounds
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Figure 2. 85 ACL Compounds Inhibit A549 Cell Viability and Proliferation, and a Subset of Compounds Including Valinomycin Selectively Kills
Lung Carcinoma Cells but Not Normal Lung Fibroblasts
(A) Effect of all 2036 compounds in the ACL on viability of A549 human lung carcinoma cells. Mean percent inhibition (of three replicates) of
calcein AM signal for each compound at each time point is plotted (blue circles), along with untreated negative control wells (red circles) and
positive control wells lacking cells (green circles). The horizontal bar indicates 50% inhibition of signal and separates active compounds from
all negative controls.
(B) Valinomycin kills lung carcinoma cells (A549) but not normal lung fibroblasts (MRC9).
(C) Dose response for valinomycin in multiple cell types.
(D) Structure of valinomycin.
terms, clinically validated anticancer mechanisms [12, gests a specific hypothesis, namely that ionophores or
a subset of ionophores are capable of killing human29–34], other cancer or cell death-related mechanisms,
as well as several mechanisms with no obvious or pre- A549 lung cancer cells. These and others compounds
in the set of 85 that inhibits the growth of A549 tumorviously recognized relationship to cell death. The identi-
fication of known anticancer mechanisms confirms the cells would not have been selected a priori as likely
to have such activity in tumor cells. For example, theinternal consistency of this automated procedure, and
the identification of unanticipated mechanisms offers “ionophore” thiomuscimol is primarily used as a GABA
receptor agonist, while narasin and nonactin are primar-the potential for finding novel associations.
Among the novel antiproliferative mechanisms gener- ily used as antiinfective agents; none of these com-
pounds are described in the literature as having strongated by this screen, the biological mechanism term “ion-
ophores” was determined to be enriched among the antiproliferative activity in human tumor cells. To quan-
tify this point directly, we determined the number of thehit compounds. The hit compounds narasin, nonactin,
thiomuscimol, and valinomycin (Figures 2B and 2C) ap- 85 active compounds that were found in at least one
Medline record with tumor or cell death-related biologi-peared in four Medline records along with the term “ion-
ophores”[35–38]. In contrast, when 85 randomly se- cal terms (tumor, tumors, carcinoma, sarcoma, adeno-
carcinoma, squamous cell carcinoma, small cell carci-lected compounds from the ACL were similarly analyzed
in 1000 repeated trials, the term ionophore was rarely noma, cell division, antineoplastic agents, cultured
tumor cells, phytogenic antineoplastic agents, apopto-associated (i.e., the term is not promiscuous). This sug-
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Figure 3. Automated Vector Annotation of
Biologically Active Compounds
(A) The table illustrates the ranking of 36
mechanism descriptors for 235 compounds.
Each row in the table represents a compound,
and each column represents a mechanism.
The top ranked mechanism for each com-
pound was colored black, the second ranked
mechanism was colored dark gray, the third
ranked mechanism was colored light gray,
and all other mechanisms were colored white.
Compound vectors were sorted in the table
by their top ranked mechanisms. The “Match
with Primary Descriptor” column was shaded
black for a compound vector if the manually
assigned primary descriptor for the com-
pound appeared as one of the top three auto-
matically ranked mechanisms.
(B) To illustrate the distribution of compounds
and mechanisms in the ACL, we highlighted
in dark gray (#1), medium gray (#2), and light
gray (#3) the top scoring three mechanisms
for each compound and performed a hierar-
chical clustering of both compound and
mechanism vectors. Large clusters of com-
pounds with the same or related mechanisms
are labeled with the name of a representative
mechanism to illustrate islands of relat-
edness in this plot of compound/mechanism
space. Non-zero entries in the rows for 85
compounds that inhibited proliferation of
A549 lung carcinoma cells are highlighted in
red, illustrating the mechanisms that block
proliferation of these cells.
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Table 3. Mechanisms for Reducing A549 Lung Carcinoma Cell Viability Identified in Global Mechanism Extraction
No. of No. of
Mechanism Score No. of Hits No. in ACL Records Hits Records ACL
General antiproliferative terms antineoplastic agents 0 15 118 27 118
growth inhibitors 0 2 14 2 7
cell cycle 0 4 50 5 58
immunosuppressive agents 0 4 38 20 43
Clinically validated mechanisms topoisomerase I 0 4 10 3 4
topoisomerase 0 5 15 4 8
tubulin 0 5 18 4 12
antimetabolites 0 4 34 7 32
protein kinase 0 13 193 12 180
DNA 0 24 305 33 612
Cancer/death-related mechanisms caspase 0 5 44 5 32
TNF 0 2 17 2 14
BRCA1 0 2 9 2 6
p53 0 4 33 3 48
oxidative phosphorylation 0 2 14 3 8
mitochondria 0 4 71 8 54
Other mechanisms ATPase 0 4 43 4 34
ionophores 0 4 28 4 23
antidepressive agents 0 3 55 4 50
potassium channel 0 5 50 6 38
protein synthesis 0 3 32 3 30
actin 0 3 26 2 28
dehydrogenase 0 6 121 11 88
PDGF 0 2 12 2 7
ATP 0 4 76 10 67
oxidants 0 2 27 3 17
antibiotics 3.E-04 9 137 8 154
cardiotonic agents 4.E-04 3 14 3 14
85 active compounds that decreased viability of A549 lung carcinoma cells were compared to all 2036 compounds in the ACL using a
procedure we termed Global Mechanism Extraction. Biological mechanism terms with statistical enrichment among these 85 compounds
(score .0004, p  0.02) are listed. For each biological mechanism term, the table lists the “score,” which is the product of (1) the percentile
score for the number of Medline records reporting that biological mechanism in this group of 85 hit compounds relative to the distribution
obtained for that mechanism when 85 randomly selected compounds are subjected to the same algorithm, and (2) the percentile score for
the number of compounds associated with each biological mechanism relative to the distribution obtained for the mechanism when 85
randomly selected compounds are subjected to the same algorithm. Also listed is the actual number of hit compounds (No. of Hits) and library
compounds (No. in ACL) that are associated with each mechanism and the number of Medline records containing both the mechanism term
and the name of a hit compound (No. of Records Hits) and the number of Medline records containing both the term and the name of any
library compound (No. of Records ACL). For more detail, see Supplemental Data at Chemistry & Biology’s website.
sis, apoptotic, antineoplastic combined chemotherapy in other cells involves introduction of double-strand DNA
breaks in a TOP1-dependent manner [39, 45–47], upreg-protocol, lung neoplasms, breast neoplasms, cell cycle,
tumor necrosis factor, cytotoxin, cytotoxic, and cytotox- ulation of TOP1 explains the increased sensitivity of
BJELR cells to camptothecin. In support of this interpre-icity). We found that for 58 of the 85 hit compounds
there was at least one Medline record listing one of tation, we found that genetic inactivation of TOP1 with
a small interfering RNA (siRNA) in BJELR cells confersthese terms and the compound name. In other words,
one-third of the compounds (27 out of 85) would not partial resistance to camptothecin [21]. Thus, in contrast
to screens with conventional libraries, screens with thehave been selected a priori as antitumor agents using
this broad definition of previously identified tumor- ACL generate hypotheses regarding biological mecha-
nisms underlying cellular phenotypes; in some casesrelated activity.
The ACL can accelerate the process of identifying these hypotheses can be validated directly.
After identifying the 85 compounds that inhibit prolif-promising candidate mechanisms underlying a biologi-
cal process, but subsequent experimental confirmation eration of A549 cells, we sought to determine whether
any of these compounds were A549 selective ratherof these proposed mechanisms remains a potentially
difficult and ad hoc procedure. The ACL has revealed than being generally cytotoxic toward many cell types.
From the group of 85 active compounds, we selectedmechanisms underlying phenotypic effects in several
studies we have undertaken, such as mechanisms that 30 compounds representing 20 biological mechanisms
for retesting in a 20-point, 2-fold dilution series in tripli-enable selective killing of BJELR engineered tumor cells
but not isogenic BJ primary cells [21]. We compared cate in both A549 lung carcinoma cells and in MRC9
normal human lung fibroblasts [48]. We calculated thethe expression levels in these two cell lines of topoisom-
erase I (TOP1), the putative target of camptothecin [11, ratio of the concentrations required in the two cell lines
for 50% inhibition of calcein AM viability dye signal,39–44], one of our BJELR-selective compounds, and
found that BJELR cells upregulate TOP1 relative to BJ yielding an A549 cell selectivity value for each com-
pound (Table 4). Compounds that were more potent incells. As camptothecin’s putative mechanism of action
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Table 4. Mechanisms for Reducing Calcein Staining in Lung Carcinoma Cells
Proposed Mechanism Mean Tumor Selectivity Compound(s)
ionophore 128 valinomycin
tubulin binding 15.5 paclitaxel, phomopsin A, podophyllotoxin, vinblastine
inhibition of glycosylation 6.4 tunicamycin
DNA synthesis 5.4 actinomycin D, echinomycin, streptonigrin, sangivamycin
phosphatases 3 phenylarsine oxide
proteases 2 (2S, 3R)-3-Amino-2-hydroxy-4-(4-nitrphenyl)butanoyl-L-leucine
protein synthesis 2 emetine, verrucarin A
ceramidase 1.6 N-oleoylethanolamine
dehydrogenase 1.5 tetraethylthiuram disulfide
nitric oxide signaling 1.4 N-p-tosyl-L-valine chloromethyl ketone
MAO 1.1 quinacrine
NFKB 1.1 parthenolide
topoisomerase II 1.1 mitoxantrone
PKC 1 chelerythrine chloride
(Na, K)-ATPase 0.8 digoxin, dihydroouabain, proscillaridin A
adenosine deaminase 0.8 N6-benzyladenosine
PP2A 0.8 cantharidin
metal chelation 0.53 2-amino-8-hydroxyquinoline
actin 0.5 cytochalasin E
topoisomerase I 0.04 camptothecin
A549 cells compared to normal MRC9 cells received a specific cellular phenotype of interest. The ability of this
analytic method to evaluate multiple mechanisms asso-selectivity ratio greater than one. Several compounds,
including those that act by binding to DNA or small ciated with a particular compound makes it a useful tool
in interpreting the effects of compounds on phenotypes.ions (i.e., with ionophore activity such as valinomycin;
Figures 2B and 2C) or by inhibiting protein glycosylation, Future annotation strategies could be broadened to inte-
grate systematic experimentation into the annotationexhibited A549 cell selectivity. These results demon-
strate that A549 lung carcinoma cells (derived from lung strategy. For example, such annotation could include
the pattern of transcriptional changes induced by a com-epithelial cells) are more sensitive than MRC9 cells (lung
fibroblasts) to killing by these compounds. This may pound or the pattern of protein binding exhibited by a
compound. In such cases, this methodology could bereflect a selectivity of these compounds and mecha-
nisms for A549 cells in particular, or it may reflect the fact applied to sift through large numbers of selected com-
pounds to determine the relevant biological mecha-that these compounds and mechanisms are selective for
lung epithelial cells over lung fibroblasts. These results nisms shared by those compounds. Moreover, the ACL
and conventional synthetic libraries provide comple-illustrate that although many compounds kill mammalian
cells nonspecifically, it is possible to identify cell-type mentary approaches for an initial phenotype-based
screen; compounds from conventional libraries can beselective compounds. In other studies, we have ex-
tended this concept to search for even more selective incorporated into the ACL once they have verified bio-
logical activity. We envision an expanding collection ofcompounds, namely those that selectively kill cells ex-
pressing one or more oncoproteins [21]. annotated compounds that define, with increasing pre-
cision, the biological molecular mechanisms that areWe recognized that valinomycin’s selectivity for A549
cells relative to MRC9 cells (Table 4) could either be due involved in regulating cellular processes.
to the reported ionophore activity of valinomycin or due
to a novel mechanism. To distinguish between these Significance
alternatives, we identified and tested five additional ion-
ophores (narasin, nigericin, salinomycin, enniatin, and Annotated compound libraries are capable of generat-
ing hypotheses regarding underlying biological mech-ammonium ionophore) for their activity in both A549 and
MRC9 cells (see Supplemental Figure S2 at Chemistry & anisms, in contrast to traditional compound libraries.
Just as in DNA microarray-based transcription profil-Biology’s website). We tested each compound in six
replicates in a dilution series in both cell lines using the ing experiments and proteomic experiments, these
hypotheses must ultimately be tested and validatedcalcein AM viability assay, and determined that these
five ionophores displayed A549-selective lethality with using conventional biological methods. It is, however,
possible to group compounds from a primary screenno detectable activity in MRC9 cells, although the maxi-
mum level of activity and the potency in A549 cells varied on the basis of their mechanistic similarity to guide
and prioritize validation studies. We demonstrate aamong the compounds. Since we observed that identifi-
cation of such A549-selective activity is uncommon (Ta- strategy for screening an annotated compound library
in cellular assays and then generating mechanisticble 4), our finding that five additional ionophores display
A549 selectivity implies that valinomycin’s selectivity is hypotheses; this strategy can likely be extended to
other cellular phenotypes. For example, we are usingdue to its ionophore activity.
In summary, we have created a method for evaluating this strategy to identify biological mechanisms under-
lying Huntington’s disease and spinal muscular atro-numerous biological mechanisms that may underlie a
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of the CB library, and the tails of the distribution are symmetricalphy using cell-based models. We propose that such
about the CB median for this particular descriptor.annotated compound libraries will prove to be an in-
creasingly valuable resource for both chemists and
Tumor Cell Viability Assay
biologists interested in performing chemical genetic A549 lung carcinoma cells or BJELR engineered tumor cells were
screens. seeded in black, clear-bottom, tissue culture-treated 384-well plates
(Costar #3712, VWR#29444-078), treated with each compound in
triplicate at 4 g/ml for 1, 2, and 3 days, washed with phosphate-
Experimental Procedures
buffered saline, and incubated for 4 hr with 0.7g/ml calcein acetox-
ylmethyl ester (calcein AM; Molecular Probes). Calcein AM is a non-
Selection and Storage of Compounds for the ACL
fluorescent compound that freely diffuses into cells and is cleaved
We assembled a collection of 2036 biologically active compounds
by intracellular esterases, generating the fluorescent anionic cal-
available from Sigma-Aldrich Co. by identifying all compounds that
cein, which is impermeable to live cell plasma membranes and is
were either (a) approved drugs or (b) had some associated annota-
therefore retained only in live cells. Total fluorescence intensity of
tion reporting biological activity. In cases where many close analogs
each well was measured on a Packard Fusion plate reader with a
or salt forms of a compound were available, three representative
485 nm excitation filter (20 nm bandpass) and a 530 nm emission
members of the compound class were chosen. We created a list of
filter (25 nm bandpass), and converted to percent inhibition of cell
structurally distinct FDA-approved small molecule drugs from the
viability by subtracting the instrument background and dividing by
electronic Orange Book [50], which is maintained by the FDA and
the average signal from untreated control cells. For dose-response
lists all drug products that have been approved for use in the United
testing, cells (A549 human lung carcinoma cells, HeLa cervical car-
States since 1938. As of December 1999, there were 19,299 products
conoma cells, BJELR engineered tumor cells, normal BJ fibroblasts,
approved by CDER (the Center for Drug Evaluation and Research
or normal MRC9 fibroblasts) were seeded at a density of 3000 cells/
within the FDA), including over-the-counter medications, prescrip-
well in 384-well plates, incubated for 2 days at 37	C with 5% CO2,tion drugs, and discontinued products. By eliminating duplicate
then processed as described above. For tumor selectivity determi-
products with the same active ingredients, we reduced this list to
nations, compounds were tested in triplicate for their effect on viabil-
1300 distinct FDA-approved drugs and purchased the 514 that were
ity of A549 lung carcinoma cells and MRC9 normal lung fibroblasts
available from Sigma-Aldrich Co. All compounds were dissolved in
in 384-well plates in a 20 point, 2-fold dilution series at a maximum
dimethylsulfoxide (DMSO) at a concentration of 4 mg/m (corre-
concentration of 4 g/ml. The ratio of concentrations required for
sponding to a concentration of 10 mM for a molecular weight of
50% inhibition of viability (IC50) was calculated (MRC9/A549) and400 g mol1) and dispensed into 384-well polypropylene plates.
the geometric mean determined when multiple compounds acting
We created an electronic archive containing both chemical and
by the same mechanism were tested (see Table 4).
biological information for each compound, including the chemical
structure, well position, plate number, FDA-approval status, com-
Microscopic Examination of Cell Deathmon name, and alternative names (see Supplemental Data at http://
Human A549 lung carcinoma cells and MRC-9 primary human lungwww.chembiol.com/cgi/content/full/10/9/881/DC1). We assigned
fibroblasts were seeded in 2 ml of medium in each well of six-wellone of 169 primary biological descriptor terms to each compound
plates at a concentration of 100,000 cells/ml. Cells were either notto categorize the general mechanism of action. These 169 primary
treated or treated with 225 nM valinomycin, incubated for 2 daysdescriptors were created manually by reading literature associated
at 37	C in the presence of 5% CO2, and photographed using phasewith each compound and creating one term that best captures that
contrast microscopy to confirm visually selective cell death in A549consensus literature view on the compound’s primary mode of ac-
cells.tion. The 99 primary descriptors associated with three or more com-
pounds are shown in Table 1 with the number of compounds in the
Annotation of Compounds with Biological Mechanismsprimary descriptor category indicated.
We obtained a local copy of the Medline biomedical literature data-
base and indexed both the 2,036 compound names in the ACL and
12,765 biological mechanism terms. We identified the number ofCalculation of Molecular Descriptor Values
times a compound name and a biological mechanism term bothTo compare the molecular descriptor ranges of the ACL with con-
occurred in an abstract, keyword, or title of a record and recordedventional synthetic libraries, we used the Molecular Operating Envi-
this number as the score for that compound name and biologicalronment (MOE) software package (Chemical Computing Group) to
mechanism pair. A searchable website containing this data is avail-electronically (1) remove counter ions by retaining only the largest
able at http://staffa.wi.mit.edu/stockwell/. Biological mechanismscovalently bound fragment, (2) adjust the protonation state to that
were scored for each compound by counting the number of ab-of the predominant species that exists at pH 7.0, (3) set atom ioniza-
stracts in Medline that contain both the compound name and ation to formal charge, and (4) add explicit hydrogens. We then re-
given biological mechanism.moved duplicate compounds and compounds with no associated
structural information from each library, reducing the ACL list from
2036 compounds to 1613 compounds with unique, available struc- Global Mechanism Extraction
Using the Medline database and a selection of hit compounds, atures. The ChemBridge (CB) library list was reduced from 30,000 to
29,996 compounds; all 20,000 compounds of Comgenex (CGX) li- single score was generated for each mechanism term that ranked
our confidence that the mechanism term was associated with the hitbrary were retained in this procedure. Using MOE, we calculated
138 molecular descriptors for each compound, including both 1D compounds in the context of the assay. Each score was computed
independently across all mechanism terms that co-occurred with(atom counts) and 2D (bond connectivity) descriptors. For each
library, the following percentiles were computed for each descriptor any hit compound name. In computing this score, we were interested
in answering two questions. First, how many of the hit compoundsvalue distribution: 1, 5, 10, 50, 90, 95, and 99. Different descriptors
have vastly disparate ranges; to facilitate comparisons over all the were associated with a given mechanism term in the literature, and
second, how many Medline records had both the mechanism termdescriptors, each descriptor was normalized to its range in one
of the libraries (CB) and also scaled to the CB median. This was and one of our hit compound names? Having many compounds
associated with a given mechanism term adds confidence that theaccomplished as follows: the unit for descriptor normalization was
the 80% range of the CB library (CB_range80), i.e., CB 90th percen- mechanism is actually relevant in the context of the assay. Similarly,
having many records in Medline containing our hit compounds andtile (CB90) minus CB 10th percentile (CB10). Percentile values for
each library were normalized and scaled for each descriptor i as in a particular mechanism term increases our confidence that this
biological mechanism is justifiably associated with the hit com-the following example: ACL90i (normalized)  ACL90i  (ACL90i 
CB mediani) / CB_range80i (see Figure 1). For example, if the ACL10 pounds. Finally, we needed to remove the underlying biases of our
compound library and Medline. For example, one of the most oftenand ACL90 for a descriptor are 1 and 1, respectively, then
ACL_range80  2, the ACL has twice the range of the 80% range used terms in Medline is “DNA.” We expect to see more associations
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between our hit compounds and this term than associations with 10. Shi, L.M., Fan, Y., Lee, J.K., Waltham, M., Andrews, D.T., Scherf,
U., Paull, K.D., and Weinstein, J.N. (2000). Mining and visualizingother terms. To overcome this problem, we generated distributions
by randomly selecting a set of 85 compounds and extracting the large anticancer drug discovery databases. J. Chem. Inf. Com-
put. Sci. 40, 367–379.collection of Medline records that refer to at least one of these
compounds. For each of 1000 iterations, we recorded, for each 11. Liu, L.F., Desai, S.D., Li, T.K., Mao, Y., Sun, M., and Sim, S.P.
(2000). Mechanism of action of camptothecin. Ann. N Y Acad.relevant mechanism term, the number of compounds in the ran-
domly selected set with the mechanism (DIST1) and the number of Sci. 922, 1–10.
12. Long, B.H., and Stringfellow, D.A. (1988). Inhibitors of topoisom-Medline records in the extracted collection with the mechanism
(DIST2). DIST1 is the expectation of observing, given a random erase II: structure-activity relationships and mechanism of ac-
tion of podophyllin congeners. Adv. Enzyme Regul. 27, 223–256.selection of compounds, the number of compounds associated with
a given mechanism. DIST2 is the expectation of observing, given 13. Miller, M.L., and Ojima, I. (2001). Chemistry and chemical biology
of taxane anticancer agents. Chem. Rec. 1, 195–211.the collection of Medline records extracted using a random set of
compounds, the number of records with a given mechanism. Given 14. Zalacain, M., Zaera, E., Vazquez, D., and Jimenez, A. (1982).
The mode of action of the antitumor drug bouvardin, an inhibitorthese two distributions, DIST1 and DIST2, we computed, given a
of protein synthesis in eukaryotic cells. FEBS Lett. 148, 95–97.selection of hit compounds, (1) the probability of finding at least the
15. Stockwell, B.R., Hardwick, J.S., Tong, J.K., and Schreiber, S.L.number of compounds observed associated with a mechanism term
(1999). Chemical genetic and genomic approaches reveal a roleand (2) the probability of finding at least the number of observed
for copper in specific gene activation. J. Am. Chem. Soc. 121,Medline records associated with both the hit compounds and a
10662–10663.given mechanism term. These two probabilities were multiplied to-
16. Mayer, T.U., Kapoor, T.M., Haggarty, S.J., King, R.W., Schreiber,gether to form the final score. A score of 0 indicates that the number
S.L., and Mitchison, T.J. (1999). Small molecule inhibitor of mi-of compounds or mechanism terms obtained for the 85 A549 hits
totic spindle bipolarity identified in a phenotype-based screen.was greater than the value obtained for that mechanism in all of the
Science 286, 971–974.1000 trials with random compounds. The full list of mechanisms and
17. Peterson, R.T., Link, B.A., Dowling, J.E., and Schreiber, S.L.scores is available at http://staffa.wi.mit.edu/stockwell/. Compound
(2000). Small molecule developmental screens reveal the logicnames were stripped of stereochemical notations, salt designations,
and timing of vertebrate development. Proc. Natl. Acad. Sci.and solvent terms. An occurrence in a Medline record indicated
USA 97, 12965–12969.an exact text match of the compound name and the biological
18. Darvas, F., Dorman, G., and Papp, A. (2000). Diversity measuresmechanism term. All biological mechanism terms that occurred at
for enhancing ADME admissibility of combinatorial libraries. J.least once with one selected compound name were listed in a table
Chem. Inf. Comput. Sci. 40, 314–322.that includes the mechanism term, the compounds found with that
19. Kohonen, T. (2001). Self-Organizing Maps, Volume 30 (Berlin:mechanism, and a link to the Medline abstracts. These statistics
Springer).are useful primarily as a guide toward expert analysis of the literature
20. Markham, P.N., Westhaus, E., Klyachko, K., Johnson, M.E., andresults. In practice, we have found that ordering the abstracts in
Neyfakh, A.A. (1999). Multiple novel inhibitors of the NorA multi-this manner has simplified searching Medline for the biological
drug transporter of Staphylococcus aureus. Antimicrob. Agentsmechanisms by which selected compounds operate.
Chemother. 43, 2404–2408.
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